Table 1 Patient characteristics
Median age (years) | 69,9 [58.6–78.3] |
|---|---|
D’Amico risk stratification | |
Low risk | 13 (21%) |
Intermediate risk | 23 (37%) |
High risk | 26 (42%) |
Median pre-treatment PSA level | 13.7 ng/mL [1.5–94] |
Gleason score | |
6 | 22 (35.5%) |
7 (3 + 4) | 18 (29%) |
7 (4 + 3) | 9 (14.5%) |
≥ 8 | 13 (21%) |
T Stage | |
T1a/b | 5 (8%) |
T1c | 27 (43.5%) |
T2 | 20 (32.5%) |
T3a | 5 (8%) |
T3b | 5 (8%) |
N Stage | |
N0 | 60 (96.7%) |
N1 | 2 (3.3%) |
Prostate surgery | |
TURP | 52 (84%) |
Vaporization | 2 (3%) |
Adenectomy | 8 (13%) |
Androgen deprivation therapy | 30 (48.5%) |
Diabete mellitus (n = 61) | 11 (18%) |
Arterial hypertension (n = 61) | 33 (54%) |
Medical treatmenta | 7 (11.3%) |
Prostatic volume before surgery (n = 59) | 59.5 cc [3–150] |
Prostatic volume after surgery (n = 54) | 26.8 cc [3–100] |
Median RT dose | 78.5 Gy [70–80] |
70 Gy | 3 (4.9%) |
76 Gy | 15 (24.2%) |
80 Gy | 44 (70.9%) |
Whole-pelvis RT | 6 (9.6%) |
Bladder volume receiving 70 Gy (n = 57) | 34.7 cc [1–86] |